NCT02478450: An ongoing trial by Q Therapeutics, Inc.
This trial is ongoing. It must report results 3 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02478450 |
|---|---|
| Title | A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS): Assessment of Localized Therapeutic Activity by Blinded Observation and Lateral Transplantation (ALTA-BOLT) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2026 |
| Completion date | Dec. 31, 2028 |
| Required reporting date | Dec. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |